1. Scrip
  2. >>Focus On Asia

De-Risking China For Foreign Life Science Investors

 
• By Jules Quartly

With $1 billion under management, Hong Kong-based private equity firm Ally Bridge Group bagged multiple deals in 2015 including WuXi's $3.3 billion privatization. ABG's CEO Frank Yu talks about pursuing a holistic approach that goes beyond ABG's China roots.

Foreign investment in Asia’s life science companies is commonplace, but investment groups operating outside the region are often viewed as being less sophisticated or liable to put their money into areas where others fear to tread.

One company seeking to reverse this preconception is Ally Bridge Group (ABG), a pioneer of the “value added cross-border investment...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

Lupin Confident Of US Growth On Tariff Mitigation, Rides High On Tolvaptan

 
• By Vibha Ravi

Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.

China’s BRL Gears Up For First CAR-T Trial In Leukemia/Lymphoma

 
• By Xu Hu

Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.

BeBetter, Trinomab Advance IPOs On China’s STAR Market In Firsts Since Policy Easing

 
• By Dexter Jie Yan

BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.

More from Scrip

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

2030’s Top Therapies: Incretin Agonists Loom Large

 
• By Edwin Elmhirst

Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.